HLA-DQ eplet mismatch load may identify kidney transplant patients eligible for tacrolimus withdrawal without donor-specific antibody formation after mesenchymal stromal cell therapy.
Sign Up to like & getrecommendations! Published in 2023 at "HLA"
DOI: 10.1111/tan.15008
Abstract: Recently, the randomized phase-II Triton study demonstrated that mesenchymal stromal cell (MSC) therapy facilitated early tacrolimus withdrawal in living donor kidney transplant recipients. The current sub-study analyzed formation of de novo donor-specific HLA antibodies (dnDSA)… read more here.
Keywords: hla eplet; hla; eplet; mismatch load ... See more keywords
Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Society of Nephrology : JASN"
DOI: 10.1681/asn.2017030287
Abstract: Despite more than two decades of use, the optimal maintenance dose of tacrolimus for kidney transplant recipients is unknown. We hypothesized that HLA class II de novo donor-specific antibody (dnDSA) development correlates with tacrolimus trough… read more here.
Keywords: trough levels; eplet mismatch; development; tacrolimus trough ... See more keywords
Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23137357
Abstract: We investigated whether HLA class II eplet mismatch was related to dnDSA development and analyzed its combined impact with tacrolimus levels for kidney transplantation outcomes. A total of 347 kidney transplants were included. HLA Matchmaker… read more here.
Keywords: hla class; development; eplet; dndsa ... See more keywords